GLP1 RT50
Investigational triple agonist targeting GLP-1, GIP and glucagon receptors — 50mg lyophilised vials for in vitro research.
| Strength | Price | Availability | Add to basket |
|---|---|---|---|
| 50mg | £105.99 | In stock |
For in-vitro laboratory research use only. Not for human or veterinary use. Not a medicine, food or cosmetic.
Retatrutide is a synthetic triple-agonist peptide analogue supplied as a lyophilised powder strictly for laboratory research and analytical evaluation. It is selected within controlled experimental settings to investigate multi-receptor kinetics across the GIP, GLP-1, and glucagon receptor pathways. Research Overview In laboratory settings, Retatrutide serves as an experimental compound for studying multi-target peptide signalling cascades. Primary research focus areas include evaluating receptor binding affinity, metabolic pathway interactions, and molecular stability across triple-agonist peptide models under controlled conditions.